Literature DB >> 24224635

Pazopanib versus sunitinib in renal cancer.

Robert J Motzer, Lauren McCann, Keith Deen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24224635     DOI： 10.1056/NEJMc1311795

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  25 in total

1.  Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma.

Authors:  R Nadal; A Amin; D M Geynisman; M H Voss; M Weinstock; J Doyle; Z Zhang; A Viudez; E R Plimack; D F McDermott; R Motzer; B Rini; H J Hammers
Journal:  Ann Oncol       Date:  2016-04-07       Impact factor: 32.976

Review 2.  Renal cell carcinoma.

Authors:  James J Hsieh; Mark P Purdue; Sabina Signoretti; Charles Swanton; Laurence Albiges; Manuela Schmidinger; Daniel Y Heng; James Larkin; Vincenzo Ficarra
Journal:  Nat Rev Dis Primers       Date:  2017-03-09       Impact factor: 52.329

3.  Patient-derived renal cell carcinoma organoids for personalized cancer therapy.

Authors:  Zhichao Li; Haibo Xu; Lei Yu; Jia Wang; Qian Meng; Hongbing Mei; Zhiming Cai; Wei Chen; Weiren Huang
Journal:  Clin Transl Med       Date:  2022-07

4.  N6-methyladenosine-modified TRAF1 promotes sunitinib resistance by regulating apoptosis and angiogenesis in a METTL14-dependent manner in renal cell carcinoma.

Authors:  Yuanlei Chen; Zeyi Lu; Chao Qi; Chenhao Yu; Yang Li; Wang Huan; Ruyue Wang; Wenqin Luo; Danyang Shen; Lifeng Ding; Liangliang Ren; Haiyun Xie; Dingwei Xue; Mingchao Wang; Kangxin Ni; Liqun Xia; Jun Qian; Gonghui Li
Journal:  Mol Cancer       Date:  2022-05-10       Impact factor: 41.444

5.  Ten years of anti-vascular endothelial growth factor therapy.

Authors:  Napoleone Ferrara; Anthony P Adamis
Journal:  Nat Rev Drug Discov       Date:  2016-01-18       Impact factor: 84.694

Review 6.  Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma.

Authors:  Kevin Zarrabi; Shenhong Wu
Journal:  Curr Oncol Rep       Date:  2018-04-02       Impact factor: 5.075

Review 7.  Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies.

Authors:  Peter Makhov; Shreyas Joshi; Pooja Ghatalia; Alexander Kutikov; Robert G Uzzo; Vladimir M Kolenko
Journal:  Mol Cancer Ther       Date:  2018-07       Impact factor: 6.261

Review 8.  Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence.

Authors:  Maxine Sun; Alessandro Larcher; Pierre I Karakiewicz
Journal:  Int J Nephrol Renovasc Dis       Date:  2014-10-29

9.  Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma.

Authors:  Martin H Voss; David Chen; Mahtab Marker; A Ari Hakimi; Chung-Han Lee; James J Hsieh; Jennifer J Knox; Maurizio Voi; Robert J Motzer
Journal:  Br J Cancer       Date:  2016-02-23       Impact factor: 7.640

Review 10.  Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement.

Authors:  Jamal Zekri; Lydia M Dreosti; Marwan Ghosn; Emad Hamada; Mohamed Jaloudi; Ola Khorshid; Blaha Larbaoui
Journal:  J Multidiscip Healthc       Date:  2015-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.